Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?

被引:26
|
作者
Markauskas, Algirdas [1 ]
Mogensen, Ole [1 ]
Christensen, Rene dePont [2 ]
Jensen, Pernille Tine [1 ]
机构
[1] Odense Univ Hosp, Dept Obstet & Gynaecol, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
Debulking surgery; Epithelial ovarian cancer; Surgical complexity; Postoperative morbidity; Survival; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; QUALITY; RISK;
D O I
10.1097/IGC.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer. Materials and Methods: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. Results: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (<= 1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months. Conclusions: We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 50 条
  • [31] Neoadjuvant chemotherapy with interval debulking surgery versus chemotherapy alone for advanced epithelial ovarian cancer
    Khouri, Olivia
    Fazzari, Melissa
    Katcher, Arielle
    Nevadunsky, Nicole
    Fife, Alexander
    Isani, Sara
    Smotkin, David
    Kuo, Dennis Yi-Shin
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S209 - S210
  • [32] Primary debulking surgery of advanced epithelial ovarian cancer in developing countries: challenges and expectations
    Purbadi, Sigit
    Saspriyana, Kade Yudi
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (01) : 26 - 29
  • [33] PROGNOSTIC MODEL FOR SURVIVAL OF EPITHELIAL OVARIAN CANCER PATIENTS TREATED WITH PRIMARY OR INTERVAL DEBULKING SURGERY
    Rutten, M. J.
    Boldingh, J. H. L.
    Schuit, E.
    Trum, H.
    Van Driel, W.
    Mol, B. W. J.
    Kenter, G. G.
    Buist, M. R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [34] PRIMARY DEBULKING SURGERY (PDS) VERSUS NEOADJUVANT CHEMOTHERAPY FOLLOWED BY INTERVAL DEBULKING SURGERY (IDS) FOR PATIENTS WITH ADVANCED OVARIAN CANCER
    Obeidat, R.
    Saidi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [35] Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis
    Chiofalo, Benito
    Bruni, Simone
    Certelli, Camilla
    Sperduti, Isabella
    Baiocco, Ermelinda
    Vizza, Enrico
    MINERVA MEDICA, 2019, 110 (04) : 330 - 340
  • [36] NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING FOR ADVANCED EPITHELIAL OVARIAN-CANCER
    JACOB, JH
    GERSHENSON, DM
    MORRIS, M
    COPELAND, LJ
    BURKE, TW
    WHARTON, JT
    GYNECOLOGIC ONCOLOGY, 1991, 42 (02) : 146 - 150
  • [37] INTERVENTION DEBULKING SURGERY IN ADVANCED EPITHELIAL OVARIAN-CANCER
    REDMAN, CWE
    WARWICK, J
    LUESLEY, DM
    VARMA, R
    LAWTON, FG
    BLACKLEDGE, GRP
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1994, 101 (02): : 142 - 146
  • [38] PRIMARY DEBULKING SURGERY VERSUS PRIMARY NEOADJUVANT CHEMOTHERAPY WITH OR WITHOUT INTERVAL DEBULKING SURGERY FOR ADVANCED STAGE OVARIAN CANCER: A SINGLE INSTITUTE STUDY
    Chen, Y. Y.
    Ou, Y. C.
    Lin, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A451 - A452
  • [39] Cytoreductive or debulking surgery in ovarian cancer: The name does matter!
    Garg, Pankaj Kumar
    Kumar, Rahul
    Choudhary, Deepti
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (08) : 1846 - 1847
  • [40] Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision-a Literature Review
    Hudry, Delphine
    Becourt, Stephanie
    Scambia, Giovanni
    Fagotti, Anna
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1661 - 1668